← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2006Last known activity
Aug 15, 2016
Acquired by Mallinckrodt (2013) on Nov 2, 2017
Timeline
2000s
- Jun 1, 2005
Ocera Therapeutics— Founded
2010s
- Jul 15, 2013
Tranzyme, Inc.— Acquired
- Nov 2, 2017
Mallinckrodt (2013)— Acquired By
Drugs by trial phase (7 distinct, 19 trials)
Phase 3 (1 own, 2 via acquisition)
Indications
Studied for
- Brain Diseases
- Emergencies
- Esophagitis, Peptic
- Fibrosis
- Fistula
- Gastroesophageal Reflux
- Hepatic Encephalopathy
- Hepatic Insufficiency
- Hyperammonemia
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Intestinal Fistula
- Irritable Bowel Syndrome
- Liver Cirrhosis
- Liver Failure
- Liver Failure, Acute
- Pouchitis
- Syndrome
- Wounds and Injuries
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (14)
- NCT03846843Lead sponsorPhase 1/Phase 2Aug 15, 2016
- NCT01966419Lead sponsorPhase 2Nov 1, 2013
- NCT01966419Study chairPhase 2Nov 1, 2013
- NCT01548690CollaboratorPhase 2Jun 1, 2012
- NCT01634230Lead sponsorPhase 2Jun 1, 2012
- NCT00867698Lead sponsorPhase 2Mar 1, 2009
- NCT00867698Study directorPhase 2Mar 1, 2009
- NCT00587275Lead sponsorPhase 2Oct 1, 2007
- NCT00558038Lead sponsorPhase 2Sep 1, 2007
- NCT00583128Lead sponsorPhase 2Aug 1, 2007
- NCT00583531Lead sponsorPhase 2Mar 1, 2007
- NCT00583076Lead sponsorPhase 2Feb 1, 2007
- NCT00321412Lead sponsorPhase 3Mar 1, 2006
- NCT00321412Study directorPhase 3Mar 1, 2006
Details
- Founded
- Palo Alto, CA, US Jun 1, 2005
- Last known activity
- Aug 15, 2016